Tag: congestive heart failure

Renal Denervation: Past, Present, and Future

Renal Denervation: Past, Present, and Future

Authors: Pourafshar, Negiin; Karimi, Ashkan; Anderson, R. David; Alaei-Andabili, Seyed Hossein; Kandzari, David E.

Over the past decade, percutaneous renal denervation has been vigorously investigated as a treatment for resistant hypertension. The SYMPLICITY radiofrequency catheter system (Medtronic CardioVascular Inc., Santa Rosa, CA, USA) is the most tested device in clinical trials. After the positive results of small phase I and II clinical trials, SYMPLICITY HTN-3 (a phase III, multi-center, blinded, sham-controlled randomized clinical trial) was completed in 2014, but did not show significant blood pressure lowering effect with renal denervation compared to medical therapy and caused the investigators and industry to revisit both the basic science elements of renal denervation as well as the design of related clinical trials. This review summarizes the SYMPLICITY trials, analyzes the SYMPLICITY HTN-3 data, and provides insights gained from this trial in the design of the most recent clinical trial, the SPYRAL HTN Global clinical trial. Other than hypertension, the role of renal denervation in the management of other disease processes such as systolic and diastolic heart failure, metabolic syndrome, arrhythmia, and obstructive sleep apnea with the common pathophysiologic pathway of sympathetic overactivity is also discussed.

DOI: http://dx.doi.org/10.15212/CVIA.2016.0016

Loading

Congestive Heart Failure Clinics: How to Make Them Work in a Community-Based Hospital System

Authors: Larned, Joshua; Kabach, Mohamad; Tamariz, Leonardo; Raimondo, Kristine

Introduction: Congestive heart failure (CHF) accounts for over $32 billion in health care costs per year and is at the epicenter of health care reform. CHF remains a major cause of hospitalizations. It is known and has been reported that missed diagnosis of and missed opportunities to treat heart failure are associated with higher mortality and morbidity. CHF disease management programs have emerged as a potential solution to the CHF epidemic. The paradox remains that CHF disease management programs still cluster in tertiary hospital systems. The impact of heart failure specialists and specialty teams in community health systems is less well understood. Currently there are not enough CHF-trained teams in the community setting to address this unmet health need.

Methods: We explored the impact of CHF clinics in a community-based hospital system on readmission rates, mortality, and symptomatic relief. A total of 384 patients were enrolled in the clinic between 2012 and 2015. Data collected included age, sex, type of heart failure, New York Heart Association class, ejection fraction, serum creatinine and brain natriuretic peptide values, and readmission and mortality rates within 30 days, 3 months, 6 months, and 1 year. We also compared readmission rates between patients who were followed up in the CHF clinic versus those who were not seen in the CHF clinic.

Results: A statistically significant difference was demonstrated in readmission rates between patients who were followed up in the CHF clinic versus those who did not visit the CHF clinic for up to 1 year of follow-up.

Conclusion: CHF community hospital clinics that use a rapid and frequent follow-up format with CHF-trained teams effectively reduce rehospitalization rates up to 1 year.

Document Type: Research Article

DOI: http://dx.doi.org/10.15212/CVIA.2015.0005

Read Full Article

Loading